Applying Functional Assay Evidence to Interpret Sequence Variants Identified in Hereditary Cancer Genes

키워드

참고문헌 (105)

1. Richards S, "Standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology", Genet Med, 17, pp.405~424 (2015)
2. Brnich SE, "Recommendations for application of the functional evidence PS3", BS3 criterion using the ACMG, Genome Med, pp.2019, 12[DOI]
3. Kanavy DM, "Comparative analysis of functional assay evidence use by ClinGen Variant Curation Expert Panels", Genome Med, 11, pp.77~ (2019)
4. Fortuno C, "Specifications of the ACMG", AMP variant interpretation guidelines for germline TP53 variants, 2021, pp.42, 223~236
5. Lee K, "Specifications of the ACMG", AMP variant curation guidelines for the analysis of germline CDH1 sequence variants, 2018, pp.39, 1553~1568
6. Mester JL, "Gene-specific criteria for PTEN variant curation : Recommendations from the ClinGen PTEN Expert Panel", Hum Mutat, 39, pp.1581~1592 (2018)
7. Starita LM, "BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number", Mol Cell Biol, 24, pp.8457~8466 (2004)
8. Ko JL, "A novel p53 mutant retained functional activity in lung carcinomas", DNA Repair(Amst), 1, pp.755~762 (2002)
9. Gilbert DF, "Cell viability assays" (2017), Sprin-ger
10. Doffe F, "Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene", Cell Death Differ, 28, pp.1477~1492 (2021)
11. Lang V, "Tetramerization-defects of p53 result in aberrant ubiquitylation and transcriptional activity", Mol Oncol, 8, pp.1026~1042 (2014)
12. Fidler IJ, "Critical determinants of metastasis", Semin Cancer Biol, 12, pp.89~96 (2002)
13. Steeg PS, "Tumor metastasis : mechanistic insights and clinical challenges", Nat Med, 12, pp.895~904 (2006)
14. Debruyne D, "Cell aggregation assays", Methods Mol Biol, 1070, pp.77~92 (2014)
15. Kramer N, "In vitro cell migration and invasion assays", Mutat Res, 752, pp.10~24 (2013)
16. Friedl P, "Plasticity of cell migration : a multiscale tuning model", J Cell Biol, 188, pp.11~19 (2010)
17. Justus CR, "In vitro cell migration and invasion assays", J Vis Exp, pp.51046~ (2014)
18. Zhang Y, "Comparative study of 3D morphology and functions on genetically engineered mouse melanoma cells", Integr Biol(Camb), 4, pp.1428~1436 (2012)
19. Spinelli L, "Assays to measure PTEN lipid phosphatase activity in vitro from purified enzyme or immunoprecipitates", Methods Mol Biol, 1447, pp.95~105 (2016)
20. el-Deiry WS, "Definition of a consensus binding site for p53", Nat Genet, 1, pp.45~49 (1992)
21. Zilfou JT, "Tumor suppressive functions of p53", Cold Spring Harb Perspect Biol, 1, pp.a001883~ (2009)
22. Riley T, "Transcriptional control of human p53-regulated genes", Nat Rev Mol Cell Biol, 9, pp.402~412 (2008)
23. Cho Y, "Crystal structure of a p53 tumor suppressor-DNA complex : understanding tumorigenic mutations", Science, 265, pp.346~355 (1994)
24. Clore GM, "High-resolution structure of the oligomerization domain of p53 by multidimensional NMR", Science, 265, pp.386~391 (1994)
25. Jeffrey PD, "Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1. 7 angstroms", Science, 267, pp.1498~1502 (1995)
26. Kato S, "Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis", Proc Natl Acad Sci U S A, 100, pp.8424~8429 (2003)
27. Giacomelli AO, "Mutational processes shape the landscape of TP53 mutations in human cancer", Nat Genet, 50, pp.1381~1387 (2018)
28. Kharaziha P, "Functional characterization of novel germline TP53 variants in Swedish families", Clin Genet, 96, pp.216~225 (2019)
29. Yamada H, "Identification and characterization of a novel germ line p53 mutation in familial gastric cancer in the Japanese population", Carcinogenesis, 28, pp.2013~2018 (2007)
30. Li J, "Mutants TP53 p. R273H and p. R273C but not p. R273G enhance cancer cell malignancy", Hum Mutat, 35, pp.575~584 (2014)
31. van Engeland M, "Annexin V-affinity assay : a review on an apoptosis detection system based on phosphatidylserine exposure", Cytometry, 31, pp.1~9 (1998)
32. Willis A, "Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes", Oncogene, 23, pp.2330~2338 (2004)
33. Brosh R, "When mutants gain new powers : news from the mutant p53 field", Nat Rev Cancer, 9, pp.701~713 (2009)
34. Pietenpol JA, "Sequence-specific transcriptional activation is essential for growth suppression by p53", Proc Natl Acad Sci U S A, 91, pp.1998~2002 (1994)
35. Vassilev LT, "In vivo activation of the p53 pathway by small-molecule antagonists of MDM2", Science, 303, pp.844~848 (2004)
36. Clarke AR, "Thymocyte apoptosis induced by p53-dependent and independent pathways", Nature, 362, pp.849~852 (1993)
37. Lukin DJ, "p53 Promotes cell survival due to the reversibility of its cell-cycle checkpoints", Mol Cancer Res, 13, pp.16~28 (2015)
38. Takaoka M, "BRCA1 gene : function and deficiency", Int J Clin Oncol, 23, pp.36~44 (2018)
39. Hashizume R, "The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation", J Biol Chem, 276, pp.14537~14540 (2001)
40. Wang B, "Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response", Science, 316, pp.1194~1198 (2007)
41. Yu X, "The C-terminal(BRCT)domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression", J Biol Chem, 273, pp.25388~25392 (1998)
42. Cantor SB, "BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function", Cell, 105, pp.149~160 (2001)
43. Humphrey JS, "Human BRCA1 inhibits growth in yeast : potential use in diagnostic testing", Proc Natl Acad Sci U S A, 94, pp.5820~5825 (1997)
44. Bork P, "A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins", FASEB J, 11, pp.68~76 (1997)
45. Elledge SJ, "Cell cycle checkpoints : preventing an identity crisis", Science, 274, pp.1664~1672 (1996)
46. Caligo MA, "A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance", Hum Mutat, 30, pp.123~133 (2009)
47. Millot GA, "Assessment of human Nter and Cter BRCA1 mutations using growth and localization assays in yeast", Hum Mutat, 32, pp.1470~1480 (2011)
48. Drost R, "BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance", Cancer Cell, 20, pp.797~809 (2011)
49. Ransburgh DJ, "Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination", Cancer Res, 70, pp.988~995 (2010)
50. Stynen B, "Diversity in genetic in vivo methods for protein-protein interaction studies : from the yeast two-hybrid system to the mammalian split-luciferase system", Microbiol Mol Biol Rev, 76, pp.331~382 (2012)
51. Sarkar M, "Re-engineering a split-GFP reassembly screen to examine RING-domain interactions between BARD1 and BRCA1 mutants observed in cancer patients", Mol Biosyst, 4, pp.599~605 (2008)
52. Starita LM, "Massively parallel functional analysis of BRCA1 RING domain variants", Genetics, 200, pp.413~422 (2015)
53. Lodovichi S, "Expression of cancer related BRCA1 missense variants decreases MMS-induced recombination in Saccharomyces cerevisiae without altering its nuclear localization", Cell Cycle, 15, pp.2723~2731 (2016)
54. Coupier I, "Fidelity of DNA double-strand break repair in heterozygous cell lines harbouring BRCA1 missense mutations", Oncogene, 23, pp.914~919 (2004)
55. Cervelli T, "Yeast-based assays for the functional characterization of cancer-associated variants of human DNA repair genes", Microb Cell, 7, pp.162~174 (2020)
56. Phelan CM, "Classification of BRCA1 missense variants of unknown clinical significance", J Med Genet, 42, pp.138~146 (2005)
57. Hayes F, "Functional assay for BRCA1 : mutagenesis of the COOH-terminal region reveals critical residues for transcription activation", Cancer Res, 60, pp.2411~2418 (2000)
58. Di Cecco L, "Characterisation of gene expression profiles of yeast cells expressing BRCA1 missense variants", Eur J Cancer, 45, pp.2187~2196 (2009)
59. Monteiro AN, "Evidence for a transcriptional activation function of BRCA1 C-terminal region", Proc Natl Acad Sci U S A, 93, pp.13595~13599 (1996)
60. Ostrow KL, "The effects of BRCA1 missense variants V1804D and M1628T on transcriptional activity", Cancer Genet Cytogenet, 153, pp.177~180 (2004)
61. Sankaran S, "BRCA1 regulates gamma-tubulin binding to centrosomes", Cancer Biol Ther, 6, pp.1853~1857 (2007)
62. Kais Z, "Regulation of centrosomes by the BRCA1-dependent ubiquitin ligase", Cancer Biol Ther, 7, pp.1540~1543 (2008)
63. Lovelock PK, "Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants", J Med Genet, 43, pp.74~83 (2006)
64. Kais Z, "Functional differences among BRCA1 missense mutations in the control of centrosome duplication", Oncogene, 31, pp.799~804 (2012)
65. Norton JA, "CDH1 truncating mutations in the E-cadherin gene : an indication for total gastrectomy to treat hereditary diffuse gastric cancer", Ann Surg, 245, pp.873~879 (2007)
66. Shore EM, "Biosynthesis of the cell adhesion molecule uvomorulin(E-cadherin)in Madin-Darby canine kidney epithelial cells", J Biol Chem, 266, pp.19672~19680 (1991)
67. van Roy F, "The cell-cell adhesion molecule E-cadherin", Cell Mol Life Sci, 65, pp.3756~3788 (2008)
68. Shenoy S, "CDH1(E-cadherin)mutation and gastric cancer : genetics, molecular mechanisms and guidelines for management", Cancer Manag Res, 11, pp.10477~10486 (2019)
69. Guilford P, "E-cadherin germline mutations in familial gastric cancer", Nature, 392, pp.402~405 (1998)
70. Corso G, "CDH1 germline mutations and hereditary lobular breast cancer", Fam Cancer, 15, pp.215~219 (2016)
71. Pharoah PD, "Incidence of gastric cancer and breast cancer in CDH1(E-cadherin)mutation carriers from hereditary diffuse gastric cancer families", Gastroenterology, 121, pp.1348~1353 (2001)
72. Barber M, "Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer", J Pathol, 216, pp.295~306 (2008)
73. Melo S, "Predicting the functional impact of CDH1 missense mutations in hereditary diffuse gastric cancer", Int J Mol Sci, 18, pp.2687~ (2017)
74. Gottardi CJ, "E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner", J Cell Biol, 153, pp.1049~1060 (2001)
75. Jeanes A, "Cadherins and cancer : how does cadherin dysfunction promote tumor progression?", Oncogene, 27, pp.6920~6929 (2008)
76. Bruner HC, "Loss of E-cadherin-dependent cell-cell adhesion and the development and progression of cancer", Cold Spring Harb Perspect Biol, 10, pp.a029330~ (2018)
77. Onder TT, "Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways", Cancer Res, 68, pp.3645~3654 (2008)
78. Yang J, "Epithelial-mesenchymal transition : at the crossroads of development and tumor metastasis", Dev Cell, 14, pp.818~829 (2008)
79. Berx G, "Involvement of members of the cadherin superfamily in cancer", Cold Spring Harb Perspect Biol, 1, pp.a003129~ (2009)
80. Saias L, "Cell-cell adhesion and cytoskeleton tension oppose each other in regulating tumor cell aggregation", Cancer Res, 75, pp.2426~2433 (2015)
81. Ozawa M, "Uvomorulin-catenin complex formation is regulated by a specific domain in the cytoplasmic region of the cell adhesion molecule", Proc Natl Acad Sci U S A, 87, pp.4246~4250 (1990)
82. Takeichi M, "Cadherins in cancer : implications for invasion and metastasis", Curr Opin Cell Biol, 5, pp.806~811 (1993)
83. Christofori G, "The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene", Trends Biochem Sci, 24, pp.73~76 (1999)
84. Suriano G, "Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands", Hum Mol Genet, 12, pp.575~582 (2003)
85. Corso G, "E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer", Eur J Cancer, 47, pp.631~639 (2011)
86. Brooks-Wilson AR, "Germline E-cadherin mutations in hereditary diffuse gastric cancer : assessment of 42 new families and review of genetic screening criteria", J Med Genet, 41, pp.508~517 (2004)
87. Jonkman JE, "An introduction to the wound healing assay using live-cell microscopy", Cell Adh Migr, 8, pp.440~451 (2014)
88. Suriano G, "E-cadherin germline missense mutations and cell phenotype : evidence for the independence of cell invasion on the motile capabilities of the cells", Hum Mol Genet, 12, pp.3007~3016 (2003)
89. Worby CA, "PTEN", Annu Rev Biochem, 83, pp.641~669 (2014)
90. Weng LP, "PTEN blocks insulin-mediated ETS-2 phosphorylation through MAP kinase, independently of the phosphoinositide 3-kinase pathway", Hum Mol Genet, 11, pp.1687~1696 (2002)
91. Weng LP, "PTEN coordinates G(1)arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model", Hum Mol Genet, 10, pp.599~604 (2001)
92. Planchon SM, "The nuclear affairs of PTEN", J Cell Sci, 121, pp.249~253 (2008)
93. Stambolic V, "Negative regulation of PKB", Akt-dependent cell survival by the tumor suppressor PTEN, 1998, pp.95, 29~39
94. Milella M, "PTEN : multiple functions in human malignant tumors", Front Oncol, 5, pp.24~ (2015)
95. Sansal I, "The biology and clinical relevance of the PTEN tumor suppressor pathway", J Clin Oncol, 22, pp.2954~2963 (2004)
96. Hlobilkova A, "Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity", Exp Cell Res, 256, pp.571~577 (2000)
97. Eng C, "PTEN : one gene, many syndromes", Hum Mutat, 22, pp.183~198 (2003)
98. Nieuwenhuis MH, "Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndrome", Fam Cancer, 13, pp.57~63 (2014)
99. Kwabi-Addo B, "Haploinsufficiency of the PTEN tumor suppressor gene promotes prostate cancer progression", Proc Natl Acad Sci U S A, 98, pp.11563~11568 (2001)
100. Álvarez-Garcia V, "Mechanisms of PTEN loss in cancer : It’s all about diversity", Semin Cancer Biol, 59, pp.66~79 (2019)
101. Han SY, "Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay", Cancer Res, 60, pp.3147~3151 (2000)
102. Mighell TL, "A saturation mutagenesis approach to understanding PTEN lipid phosphatase activity and genotype-phenotype relationships", Am J Hum Genet, 102, pp.943~955 (2018)
103. Sun H, "PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3, 4, 5, -trisphosphate and Akt", protein kinase B signaling pathway, 1999, pp.96, 6199~6204
104. Tan MH, "A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands", Am J Hum Genet, 88, pp.42~56 (2011)
105. Spinelli L, "Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes", J Med Genet, 52, pp.128~134 (2015)

관련 논문AI추천